Knottin Scaffold Peptides for Integrin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current integrin-binding peptides, such as RGD peptides, have limitations in affinity and specificity for integrins like αvβ3, αvβ5, and α5β1, which are crucial for angiogenesis and cancer therapy, and there is a need for improved molecules that can effectively target these integrins for therapeutic and imaging applications.
Innovation Solution
Engineered peptides with a knottin protein scaffold and an integrin binding loop containing the RGD sequence, optimized through directed evolution and molecular engineering, provide high affinity and specificity for αvβ3, αvβ5, and α5β1 integrins, with the loop length and flanking residues critical for binding efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If linear RGD peptides are used, then simplicity of structure is maintained, but binding affinity for integrins is low
Solution Approach 1:
The patent applies parameter changes by modifying the peptide structure from linear to cyclic form, introducing disulfide bonds to constrain the peptide into a specific three-dimensional conformation. This structural parameter change dramatically increases binding affinity for integrins while maintaining the essential RGD sequence functionality.
Solution Approach 2:
The patent creates composite peptide structures by combining the RGD binding motif with specific flanking sequences and cyclic constraints. The resulting cyclic RGD peptides represent a composite structure that integrates multiple functional elements (RGD sequence, flanking residues, disulfide bonds) to achieve enhanced integrin binding affinity.
2Reliability
If RGD peptides are used, then integrin binding capability is achieved, but specificity for particular integrin subtypes is insufficient
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the peptide sequence (flanking residues) surrounding the RGD motif. Different flanking sequences are designed to target specific integrin subtypes (αvβ3, αvβ5, α5β1), creating locally optimized peptide structures that achieve high specificity for particular integrin receptors.
Solution Approach 2:
The patent uses parameter changes by systematically varying the amino acid composition and sequence length of flanking regions to tune specificity for different integrin subtypes. This allows the same RGD core motif to be adapted for highly specific binding to different integrin family members through controlled sequence parameter modifications.
3Strength
If cyclic RGD motifs with disulfide bonds are used, then binding affinity increases, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-forming disulfide bonds during peptide synthesis to create the cyclic structure. This preliminary structural constraint is established before final purification and application, simplifying the overall manufacturing process by avoiding the need for post-synthesis cyclization steps.
Data Source
AI summary
Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α5β1) or vitronectin (αvβ3 and αvβ5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.